Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

Studies on the biologic and molecular genetic underpinnings of multiple myeloma (MM) have identified the pleiotropic, pro-inflammatory cytokine, interleukin-6 (IL-6), as a factor crucial to the growth, proliferation and survival of myeloma cells. IL-6 is also a potent stimulator of osteoclastogenesi...

Full description

Saved in:
Bibliographic Details
Published in:Immunologic research 2014-08, Vol.59 (1-3), p.188-202
Main Authors: Rosean, Timothy R., Tompkins, Van S., Tricot, Guido, Holman, Carol J., Olivier, Alicia K., Zhan, Fenghuang, Janz, Siegfried
Format: Article
Language:English
Subjects:
Allergology
Animals
Antineoplastic Agents - immunology
Antineoplastic Agents - therapeutic use
Biomedical and Life Sciences
Biomedicine
Cytokines
Drug Screening Assays, Antitumor
Humans
Immunology
Immunology at the University of Iowa
Interleukin-6 - immunology
Interleukin-6 - therapeutic use
Internal Medicine
Medicine/Public Health
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - immunology
Multiple Myeloma - pathology
Plasma Cells - immunology
Plasma Cells - pathology
Portraits as Topic
Tumor Microenvironment - drug effects
Tumor Microenvironment - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Studies on the biologic and molecular genetic underpinnings of multiple myeloma (MM) have identified the pleiotropic, pro-inflammatory cytokine, interleukin-6 (IL-6), as a factor crucial to the growth, proliferation and survival of myeloma cells. IL-6 is also a potent stimulator of osteoclastogenesis and a sculptor of the tumor microenvironment in the bone marrow of patients with myeloma. This knowledge has engendered considerable interest in targeting IL-6 for therapeutic purposes, using a variety of antibody- and small-molecule-based therapies. However, despite the early recognition of the importance of IL-6 for myeloma and the steady progress in our knowledge of IL-6 in normal and malignant development of plasma cells, additional efforts will be required to translate the promise of IL-6 as a target for new myeloma therapies into significant clinical benefits for patients with myeloma. This review summarizes published research on the role of IL-6 in myeloma development and describes ongoing efforts by the University of Iowa Myeloma Multidisciplinary Oncology Group to develop new approaches to the design and testing of IL-6-targeted therapies and preventions of MM.
ISSN:0257-277X
1559-0755
DOI:10.1007/s12026-014-8528-x